Sign in

CIK 0001157601

  • Large accelerated filer

MADRIGAL PHARMACEUTICALS, INC.

Sign in to watch
Ticker
MDGL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 267-824-2827
Business address
1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
Former names
MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
Open-market buys, last 90 days
$35,023,032
in 1 filing
Open-market sales, last 90 days
$6,669,998
in 2 filings, $6.7M under 10b5-1 plans

Net +$28,353,034. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2025-03-05 Waltermire Robert E. Senior VP, Chief Pharma Dev. Option exercise +6,825 $87.92 $600K 10,553
2025-03-05 Waltermire Robert E. Senior VP, Chief Pharma Dev. Option exercise +7,288 $87.09 $635K 17,841
2025-03-05 Waltermire Robert E. Senior VP, Chief Pharma Dev. Sale −900 $335.15 $302K 16,941
2025-03-05 Waltermire Robert E. Senior VP, Chief Pharma Dev. Sale −1,777 $336.78 $598K 15,164
2025-03-05 Waltermire Robert E. Senior VP, Chief Pharma Dev. Sale −1,146 $338.09 $387K 14,018
2025-03-05 Waltermire Robert E. Senior VP, Chief Pharma Dev. Sale −400 $339.68 $136K 13,618
2025-03-05 Waltermire Robert E. Senior VP, Chief Pharma Dev. Sale −1,657 $340.75 $565K 11,961
2025-03-05 Waltermire Robert E. Senior VP, Chief Pharma Dev. Sale −1,043 $341.84 $357K 10,918
2025-03-05 Waltermire Robert E. Senior VP, Chief Pharma Dev. Sale −1,077 $342.90 $369K 9,841
2025-03-05 Waltermire Robert E. Senior VP, Chief Pharma Dev. Sale −4,701 $343.85 $1.6M 5,140
2025-03-05 Waltermire Robert E. Senior VP, Chief Pharma Dev. Sale −1,412 $344.76 $487K 3,728
2025-03-05 Waltermire Robert E. Senior VP, Chief Pharma Dev. Grant or award +2,061 5,789
2025-03-05 Waltermire Robert E. Senior VP, Chief Pharma Dev. Option exercise · Stock Option (Right to Buy) −6,825 4,375
2025-03-05 Waltermire Robert E. Senior VP, Chief Pharma Dev. Option exercise · Stock Option (Right to Buy) −7,288 3,062
2025-03-05 Waltermire Robert E. Senior VP, Chief Pharma Dev. Grant or award · Stock Option (Right to Buy) +1,157 1,157
2025-02-28 Waltermire Robert E. Senior VP, Chief Pharma Dev. Sale −1,052 $340.99 $359K 3,903
2025-02-28 Waltermire Robert E. Senior VP, Chief Pharma Dev. Sale −175 $341.55 $60K 3,728
2025-01-24 Waltermire Robert E. Senior VP, Chief Pharma Dev. Sale −103 $335.24 $35K 4,955
2025-01-17 Waltermire Robert E. Senior VP, Chief Pharma Dev. Sale −442 $273.41 $121K 5,058
2024-06-14 Waltermire Robert E. Senior VP, Chief Pharma Dev. Option exercise +1,900 $87.09 $165K 7,400

Page 1 of 3 · 59 trades